Eli Lilly and stock
Price history
+41.12% over the period1 year: from $1,022.87 (November 13, 2025) to $1,443.50 (November 13, 2026), +41.12%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $1,443.50 |
| October 30, 2026 | $1,417.54 |
| September 30, 2026 | $1,157.08 |
| August 31, 2026 | $1,156.73 |
| July 31, 2026 | $1,148.84 |
| June 30, 2026 | $1,199.43 |
| May 29, 2026 | $1,105.00 |
| April 30, 2026 | $934.60 |
| March 31, 2026 | $919.77 |
| February 27, 2026 | $1,051.99 |
| January 30, 2026 | $1,037.15 |
| December 31, 2025 | $1,074.68 |
| November 28, 2025 | $1,075.47 |
| November 13, 2025 | $1,022.87 |
At a glance
The company
Discovers, develops, manufactures and markets human pharmaceutical products for diabetes, obesity, oncology, immunology and neurology
Latest results
Quarter to September 30, 2026 · EPS $7.48 (estimate $9.92)
TickerLandia's take on Eli Lilly and
- Pricier than usual relative to earnings: P/E on the latest fiscal year 63 vs a median of 45 over its last 9 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 47 vs 42 (+11%) in a group of 10.
- Strong point: Profitability (96/100 in its group). Weak point: Earnings stability (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.13% from the 52-week high
Analysts · 31 analysts
Average target$1,463.40+1.38% vs. price
Buy 25 · Hold 4 · Sell 2 · Buy
TickerLandia Fingerprint: Eli Lilly and
Compared with similar companies: very high profitability, very high price, and very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricevery high94
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 46.9 85 Forward P/E 28.5 94 Price/book 31.9 98 Price/sales 14.9 98 EV/EBITDA 28.6 98 Profitabilityvery high96
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 51.3% 98 Gross margin 83.6% 98 Net margin 31.9% 90 ROE 86.0% 98 ROA 21.1% 94 Earnings stabilitylow34
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 7.0% 14 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthvery high83
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +31.69% 98 Revenue growth (year over year) +38.60% 94 Earnings growth (year over year) +16.30% 56 Financial strengthaverage55
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.15 46 Interest coverage 115.7 94 Current ratio 1.39 54 Debt/equitycounts in reverse: lower means more financial strength 1.23 27 Dividendlow37
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 90 Dividend yield 0.5% 10 Payout ratio 22.5% 10 Market momentumvery strong91
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +23.14% 94 Relative strength (6 months) +39.90% 91 1-year return +41.12% 82 Distance from 200-day average +30.12% 97 Risklow35
How much the price swings.
Metric Value Position in group Beta (1 year) 0.33 33 Volatility (60 days) 29.4% 37 Maximum drawdown (12 months) 23.3% 36
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Eli Lilly and is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Eli Lilly and's P/E today is 62.9, above the median of its last 9 fiscal years (45.1; between 14.8 and 100.5 from 2016 to 2025). Eli Lilly and's P/E (trailing 12 months): 46.9, +11% against the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Eli Lilly and | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 46.9 | Middle | |
| Forward P/E | 28.5 | High | |
| Operating margin | 51.3% | High | |
| ROE | 86.0% | High | |
| Debt/equity | 1.23 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Eli Lilly and. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$24.4B
Latest quarter · Q3 2026
Net income
$6.45B
Latest quarter · Q3 2026
Quarterly net margin
26.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $1.29T
- P/E
- 46.9
- EPS
- $30.81
- Volume
- 1.87M
- Daily trading
- €3.67B
- Dividend yield
- 0.48%
- Last ex-dividend on November 13, 2026
How Eli Lilly and is changing
All resultsRevenue grew 21.6% a year on average over the last 5 years
Operating margin rose from 30.3% to 45.6%
Less cash than profit: free cash flow equal to 37% of net income
Returns
Eli Lilly and returns with dividends
$1,000 invested in Eli Lilly and 5 years ago, on November 15, 2021, would be worth $5,832 today with dividends reinvested: +483.19% in total, +42.35% per year. On price alone it would be $5,586 (+458.57%).
| Period | Eli Lilly and | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +23.75% | −3.12% | $1,237 |
| 6 months | +42.11% | +1.58% | $1,421 |
| Year to date | +34.32% | +10.46% | $1,343 |
| 1 year | +42.19% | +12.23% | $1,422 |
| 3 years | +140.77% | +71.41% | $2,408 |
| 5 years | +483.19% | +61.48% | $5,832 |
| 10 years | +2,080.10% | +249.40% | $21,801 |
Over the last 6 months it has done better than 80% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Eli Lilly and: technical analysis
Eli Lilly and is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its highest close since January 2, 1990.
- Trend
- Upward
- RSI (14 sessions)
- 70
- Between 30 and 70
- vs 200-session average
- +30.12%
Support and resistance
Price areas where Eli Lilly and has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$1,443.50
- Support$1,223.50−15.24%2 touches, last on September 30, 2026
- Support$1,173.11−18.73%2 touches, last on August 17, 2026
- Support$1,137.16−21.22%4 touches, last on October 8, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.33
- Volatility (60 sessions, annualised)
- 29.4%
- Largest fall in the last year
- −23.31%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Eli Lilly and: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Eli Lilly and has been November: +3.40% on average, positive in 27 years out of 36. The weakest has been February: −0.89% on average, positive in 17 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.40% | −0.36% | 18 of 36 |
| February | −0.89% | −1.26% | 17 of 37 |
| March | +0.25% | +1.04% | 22 of 37 |
| April | +2.43% | +1.61% | 22 of 37 |
| May | +1.66% | −0.19% | 16 of 37 |
| June | +2.80% | +3.43% | 24 of 37 |
| July | −0.10% | +1.09% | 22 of 37 |
| August | +0.58% | −0.98% | 16 of 37 |
| September | +0.93% | +0.03% | 19 of 37 |
| October | +1.34% | +1.05% | 21 of 37 |
| November | +3.40% | +2.59% | 27 of 36 |
| December | +3.06% | +1.05% | 20 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Eli Lilly and and its competitors
Insulin brands Humalog and Humulin, together with the diabetes and obesity medicines Mounjaro, Trulicity and Zepbound, are among the best-known products of Eli Lilly and Company. The group also sells cancer treatments such as Verzenio, Jaypirca and Erbitux, immunology drugs including Taltz and Omvoh, and Kisubla for symptomatic Alzheimer's disease. Its prescription medicines reach customers in the United States, Europe, China, Japan and other markets worldwide, and the company works with partners such as Boehringer Ingelheim on the Jardiance family.
- Headquarters
- Indianapolis, United States
- Employees
- 50,000
- Founded
- 1876
- Chief executive
- David Ricks
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Eli Lilly andLLY | $1.29T | 51.3% | 46.9 | +42.11% |
| Johnson & JohnsonJNJ | $687.89B | 26.6% | 43.4 | +24.01% |
| AbbVieABBV | $521.5B | 36.6% | 50.6 | +41.50% |
| MerckMRK | $364.26B | 35.2% | 147.8 | +30.24% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
Same industry or related industries, similar size. Compare Eli Lilly and with its competitors · Full profile
